Results 151 to 160 of about 119,519 (336)

The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review

Dermatology and Therapy
Alopecia areata is an inflammatory autoimmune disease that presents as non-scarring hair loss in adults and children and causes substantial psychological distress, economic burden, and reduced quality of life for those affected.
Hussein Abdel Dayem, Anwar Al Hammadi, Ashraf Reda, Fatima Albreiki, Ayman Al Naeem, Ahmed Ameen, Mohamed Ahmed, Huda Rajab Ali, Mohamed Elrayes, Gozde Senay, Muna Al Murrawi   +10 more
doaj   +1 more source

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son, Yves Julien Mbama Biloa, Pauline Gouttefarde, Thomas Franck, Gilles Cizeron, Mathieu Oriol, François Maccari, Elisa Cinotti, Beatrice Trombert‐Paviot, Bienvenu Bongue, Jean‐Luc Perrot   +10 more
wiley   +1 more source

Profile of pacritinib and its potential in the treatment of hematologic disorders

Journal of Blood Medicine, 2014
Eleftheria Hatzimichael, Evangelos Tsolas, Evangelos Briasoulis Department of Haematology, University Hospital of Ioannina, Ioannina, Greece Abstract: Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and ...
Hatzimichael E, Tsolas E, Briasoulis E
doaj  

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

Narrow spectrum kinase inhibitors demonstrate promise for the treatment of dry eye disease and other ocular inflammatory disorders [PDF]

, 2018
Doughty, Michael, Foster, Martyn R., Fyfe, Matthew C.T., Hagan, Suzanne, Ofori-Frimpong, Boatemaa, Oliver, Katherine, Rowley, Adele, Sirohi, Sameer, Solanke, Yemisi, Taylor, Mike, Walshe, Claire A., Webber, Steve   +11 more
core   +1 more source

Leukemia Inhibitory Factor Represses GnRH Gene Expression via cFOS during Inflammation in Male Mice. [PDF]

, 2019
BackgroundThe mechanisms whereby neuroinflammation negatively affects neuronal function in the hypothalamus are not clear. Our previous study determined that obesity-mediated chronic inflammation elicits sex-specific impairment in reproductive function ...
Coss, Djurdjica, Lainez, Nancy M
core   +1 more source

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

, 2016
Eugene Guorong Yang, Nurulhuda Mustafa, Eng Chong Tan, Anders Poulsen, Pondy Murugappan Ramanujulu, Wee Joo Chng, J. J. Yen, Brian Dymock   +7 more
openalex   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Levetiracetam Reduces Early Inflammatory Response After Experimental Intracerebral Hemorrhage by Regulating the Janus Kinase 2 (JAK2)–Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway

, 2020
Jing Xiong, Han Zhou, Donglin Lu, Zixuan Wang, Heng-Jian Liu, Yuqi Sun, Jinxiang Xu, Yugong Feng, Ang Xing   +8 more
openalex   +1 more source

Inibidores da Janus Kinase na alopecia areata: uma nova possibilidade terapêutica

, 2021
Amanda Tauana Oliveira e Silva, Letícia Nunes Tajra, Denise Coelho de Almeida, Maysa Mauriz de Galiza Robatini Ramos, Myrna Beatriz de Melo Oliveira, Anna Carolina Miola   +5 more
openalex   +2 more sources